Skip to main content
. 2012 Jul;2(7):a009449. doi: 10.1101/cshperspect.a009449

Figure 5.

Figure 5.

Genomics will play an integral role in the development of personalized therapeutics. The availability of detailed phenotype data from large patient/control cohorts is an important prerequisite for high-throughput genetic screening studies, including GWAS and genomic sequencing. After genetic risk loci have been dissected, in silico, in vitro, and in vivo analyses establish the underlying functional pathways and help to posit targets for rational, personalized therapies.